ITOS: iTeos Therapeutics, Inc.
About
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Current Value
$8.011 Year Return
Current Value
$8.011 Year Return
Key Details
Market Cap
$288.62M
P/E Ratio
-2.51
1Y Stock Return
-19.06%
1Y Revenue Growth
-47.37%
Dividend Yield
0.00%
Price to Book
0.5
Strategies that include ITOS
Stock's related to ITOS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NVAX | 48.55% | $1.28B | +49.53% | 0.00% |
| MTD | 46.56% | $24.49B | +6.92% | 0.00% |
| CDNA | 41.58% | $1.18B | +132.21% | 0.00% |
| GEN | 41.44% | $18.02B | +38.78% | 1.71% |
| ADMA | 40.56% | $4.88B | +423.60% | 0.00% |
| CTLP | 39.55% | $653.23M | +34.18% | 0.00% |
| OUST | 39.25% | $448.93M | +87.53% | 0.00% |
| RCUS | 38.37% | $1.33B | +5.07% | 0.00% |
| ORGO | 37.90% | $540.91M | +59.38% | 0.00% |
| GH | 37.28% | $3.79B | +33.86% | 0.00% |
| GRVY | 36.23% | $466.13M | -4.24% | 0.00% |
| BMRN | 35.91% | $11.81B | -29.63% | 0.00% |
| SUNS | 35.45% | $105.89M | +35.31% | 1.37% |
| SG | 35.14% | $4.38B | +299.68% | 0.00% |
| ONL | 33.40% | $218.76M | -20.85% | 10.31% |
| PGEN | 31.89% | $228.91M | -28.00% | 0.00% |
| ALEC | 31.87% | $377.04M | -19.46% | 0.00% |
| MRSN | 31.68% | $274.24M | +40.51% | 0.00% |
| FATE | 30.35% | $248.29M | -11.02% | 0.00% |
| RMAX | 30.02% | $215.33M | +23.09% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OXBR | <0.01% | $19.05M | +178.18% | 0.00% |
| UFI | <0.01% | $102.66M | -11.22% | 0.00% |
| ZH | 0.02% | $333.09M | -40.59% | 0.00% |
| ACGL | 0.02% | $36.00B | +16.84% | 0.00% |
| CYD | -0.06% | $364.46M | -2.94% | 4.26% |
| SWI | -0.07% | $2.22B | +22.97% | 0.00% |
| DADA | -0.07% | $367.07M | -63.71% | 0.00% |
| RYAAY | -0.08% | $24.60B | -2.90% | 0.00% |
| SDRL | 0.09% | $2.74B | -4.48% | 0.00% |
| PETS | 0.09% | $93.60M | -41.21% | 0.00% |
| MODV | -0.09% | $222.68M | -59.06% | 0.00% |
| PAGP | -0.10% | $3.67B | +16.79% | 0.00% |
| SHOP | -0.10% | $135.10B | +49.99% | 0.00% |
| USAC | -0.11% | $2.76B | -3.87% | 8.93% |
| FWONA | -0.12% | $18.48B | +27.70% | 0.00% |
| PRDO | -0.12% | $1.73B | +56.77% | 1.74% |
| EG | -0.14% | $15.92B | -8.98% | 2.02% |
| CMBM | -0.14% | $30.22M | -75.23% | 0.00% |
| TALO | 0.15% | $1.98B | -20.99% | 0.00% |
| LPG | 0.16% | $1.10B | -31.36% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FAT | -25.58% | $89.30M | -11.53% | 10.73% |
| MGNX | -24.62% | $218.42M | -53.04% | 0.00% |
| OKLO | -24.34% | $2.66B | +111.04% | 0.00% |
| FATBB | -23.60% | $81.94M | -12.91% | 11.69% |
| CME | -17.24% | $82.76B | +9.21% | 1.98% |
| SOLV | -15.30% | $11.58B | -16.19% | 0.00% |
| AKAM | -14.41% | $13.12B | -22.78% | 0.00% |
| SLF | -11.84% | $34.74B | +18.95% | 3.89% |
| YPF | -11.64% | $13.98B | +139.72% | 0.00% |
| FROG | -11.54% | $3.34B | +11.67% | 0.00% |
| XPOF | -11.18% | $504.00M | +11.50% | 0.00% |
| KRP | -10.86% | $1.29B | +2.58% | 11.03% |
| AVD | -10.69% | $182.80M | -32.45% | 1.42% |
| MSDL | -10.57% | $1.83B | +0.66% | 7.26% |
| NGL | -10.30% | $572.94M | +5.60% | 0.00% |
| MVIS | -10.01% | $198.19M | -60.14% | 0.00% |
| CMG | -9.94% | $80.02B | +33.62% | 0.00% |
| HUSA | -9.93% | $16.69M | -11.56% | 0.00% |
| PULM | -9.20% | $19.83M | +202.98% | 0.00% |
| VHC | -9.00% | $19.06M | -38.36% | 0.00% |
ETF's related to ITOS
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DUSB | 0.04% | $797.63M | 0.15% |
| AGZD | -0.06% | $142.76M | 0.23% |
| DBA | -0.11% | $755.88M | 0.93% |
| VRP | 0.14% | $1.83B | 0.5% |
| FTXN | -0.16% | $179.41M | 0.6% |
| IBHD | 0.17% | $327.80M | 0.35% |
| FTSD | 0.18% | $171.68M | 0.25% |
| PSCE | 0.19% | $91.62M | 0.29% |
| XLE | 0.20% | $37.90B | 0.09% |
| IXC | -0.22% | $2.20B | 0.41% |
| MLPA | -0.36% | $1.64B | 0.45% |
| PWZ | 0.37% | $697.36M | 0.28% |
| VDE | 0.38% | $8.33B | 0.1% |
| FLRN | -0.39% | $2.33B | 0.15% |
| SEIX | 0.39% | $268.81M | 0.62% |
| CPER | -0.41% | $159.52M | 0.97% |
| OIH | 0.50% | $1.69B | 0.35% |
| FENY | 0.61% | $1.64B | 0.084% |
| IYE | 0.68% | $1.35B | 0.39% |
| IBTE | 1.00% | $1.70B | 0.07% |
News
Yahoo
Last week, you might have seen that iTeos Therapeutics, Inc. ( NASDAQ:ITOS ) released its third-quarter result to the...
Yahoo
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO- Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination- Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful
Yahoo
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in G
SeekingAlpha
The S&P 500 notched its 39th record high on Thursday, reaching 5713. September got off to a shaky start but it is now in the green. Click to read.
SeekingAlpha
The 'Undercovered' Dozen series highlights 12 undercovered stocks to provide another source for investment ideas and to encourage community discussion. Read more here.
Yahoo
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.